Developing novel precision oncology therapeutics

葆元医药是一家临床阶段生物制药公司,管理团队具备药品全球临床开发的成功经验。葆元医药专注于开发针对肿瘤领域,未满足临床需求的药品。

Our mission is to develop a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need. Our vision is to become a global leader in personalized oncology medicine by leveraging our expertise in clinical research, development and product registration.

研发管线

目前,葆元医药的研发管线包括三个临床阶段药物:

  • Taletrectinib AB-106: 第二代ROS1&NTRK双靶点抑制剂,目前处于临床Ⅱ期试验阶段
  • mIDH1 inhibitor AB-218: 进入临床Ⅱ期试验阶段,适应症包括较低级别脑胶质瘤、胆管癌、急性粒细胞白血病(AML)等肿瘤
  • AXL inhibitor AB-329: 目前处于临床I期试验阶段 用于克服多种肿瘤中免疫检查点抑制剂或EGFRi耐药问题